{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.1","upperLimit":"15.1","value":"12.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of molecular response 4.5 (MR4.5). Participants who did not regain MR4.5 after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment. MR4.5 corresponds to a BCR-ABN transcript level ≤0.0032% on the International Scale (IS).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who experienced loss of major molecular response during the treatment-free remission (TFR) phase entered the nilotinib treatment re-initiation (NTRI) phase. During this phase, nilotinib treatment was re-initiated at a dose of 300 mg twice daily.","id":"OG000","title":"NTRI Phase"}],"paramType":"MEDIAN","populationDescription":"The nilotinib treatment re-initiation (NTRI) safety set included all participants who received at least one dose of study medication during the nilotinib treatment re-initiation phase.","reportingStatus":"POSTED","timeFrame":"From start of Nilotinib treatment re-initiation up to Week 528","title":"Duration of Re-Initiated Nilotinib Treatment Required to Regain Molecular Response 4.5 (MR4.5) After Loss of MMR","type":"SECONDARY","unitOfMeasure":"Weeks"}